Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Radiotherapy for Adjuvant ESCC
NCT04741490Unknown
- Sponsor
- 900th Hospital of Joint Logistics Support Force of PLA
- Start
- Feb 2021
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by 900th Hospital of Joint Logistics Support Force of PLA. Primary endpoint: 1-year disease-free survival rate. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04741490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04741490.